Position in EXEL
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$332,183
+$30,852 QoQ
Shares Held
7,745
+12.7% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.19%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Rossby Financial, LCC holds $1,092,342 across 49 Biotechnology names. EXEL ranks #1 (30.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
This page
|
7,745 | $332,183 | |
| 2 | INSM |
INSMED Inc
|
1,033 | $168,916 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
228 | $101,811 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
126 | $97,352 | |
| 5 | GMAB |
Genmab A/S
|
3,266 | $87,626 | |
| 6 | ARGX |
Argenx SE
|
87 | $63,531 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
143 | $47,314 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
84 | $15,880 |
All Filings in EXEL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $332,183 | 7,745 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $301,331 | 6,875 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $281,666 | 6,820 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $130,036 | 2,950 | Shares | Sole | 2025-08-01 | |
| 2025-03-31 | $107,474 | 2,911 | Shares | Sole | 2025-04-28 | |
| No filing history on record for this holder in this stock. | ||||||